<DOC>
	<DOCNO>NCT02581189</DOCNO>
	<brief_summary>This study seek provide evidence effectiveness obtain patient report outcome ( PRO ) data interferon-free ABBVIE REGIMEN ± RBV participant chronic hepatitis C ( CHC ) real life set across clinical practice patient population Canada .</brief_summary>
	<brief_title>Effectiveness Paritaprevir/r - Ombitasvir , ± Dasabuvir , ± Ribavirin Patients With Chronic Hepatitis C Canada</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Confirmed , CHC , genotype 1 4 , treatmentnaïve experience participant receive combination therapy interferonfree ABBVIE REGIMEN ± RBV If RBV coadministered ABBVIE REGIMEN , prescribe line current local label ( special attention contraception requirement contraindication pregnancy ) Participants must voluntarily sign date participant authorization use and/or disclose his/her anonymized health data prior inclusion study Patient participate intend participate concurrent interventional therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Patient report outcome</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Influence adherence</keyword>
	<keyword>Genotype 1 4</keyword>
</DOC>